William Barnard
Internal Medicine · Grandview, MONPI 1396742110
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 98.6% of the total across 70 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 23 manufacturers, the largest accounting for just 15.8% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $453 and has fallen 77.7% since, to $101 in 2022.
Across 70 payments — averaging $14.23 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$157
- Novo Nordisk$114
- Amgen$111
- AstraZeneca$86
- Shire North American Group Inc$61
- Lilly USA, LLC$58
- plus $408 from 17 others
What the payments were for
- Food & beverage$98299%
- Education$141%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 9 | $157 |
| Novo Nordisk | 9 | $114 |
| Amgen | 8 | $111 |
| AstraZeneca | 7 | $86 |
| Shire North American Group Inc | 4 | $61 |
| Lilly USA, LLC | 4 | $58 |
| Adlon Therapeutics L.p. | 4 | $52 |
| Pfizer | 4 | $48 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $41 |
| Biohaven Pharmaceuticals, Inc. | 2 | $38 |
| Ironshore Pharmaceuticals Inc. | 2 | $34 |
| Antares Pharma, Inc. | 2 | $29 |
| GSK | 2 | $23 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $18 |
| Novartis | 1 | $17 |
| Merck | 1 | $17 |
| Amarin Pharma, Inc. | 1 | $15 |
| Sanofi-aventis U.S. LLC | 1 | $15 |
| Phadia US Inc. | 1 | $14 |
| Intersect ENT, Inc. | 1 | $12 |
| Genentech USA, Inc. | 1 | $12 |
| Nevro Corp. | 1 | $12 |
| Upsher-smith Laboratories LLC | 1 | $11 |
How this compares
$996 in reported general payments places this provider in the 70th percentile of 2,097 internal medicine providers in Missouri.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Atorvastatin Calcium | 18 | $495 |
| Amlodipine Besylate | 11 | $62 |
Paid to pharmacies, not to this prescriber.
Other internal medicine in Grandview
- Washington MuroGrandview$27K
- Timothy SmithSaint Peters$428K
- Craig DietzKansas City$226K
- Kevin SuttmoellerKansas City$198K
- Vinay KamatSaint Louis$191K
- David PrelutskySaint Louis$182K
- Dima DandachiColumbia$157K
- Justin SteinkampSaint Charles$139K
- Tracy NorfleetSaint Louis$132K
- Paul OlivoSaint Louis$98K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.